42.495 USD
-0.1 (-0.22%)
Last: Feb 4, 2026, 12:39 PM
We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 524 industry peers in the Biotechnology industry. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EXEL is growing strongly while it also seems undervalued. This is an interesting combination This makes EXEL very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
- EXEL had positive earnings in the past year.
- EXEL had a positive operating cash flow in the past year.
- Each year in the past 5 years EXEL has been profitable.
- In the past 5 years EXEL always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of EXEL (24.01%) is better than 97.52% of its industry peers.
- The Return On Equity of EXEL (31.37%) is better than 97.71% of its industry peers.
- EXEL has a better Return On Invested Capital (26.31%) than 98.86% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 18.09%.
- The last Return On Invested Capital (26.31%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
- The Profit Margin of EXEL (29.63%) is better than 95.80% of its industry peers.
- In the last couple of years the Profit Margin of EXEL has declined.
- EXEL has a better Operating Margin (35.85%) than 97.71% of its industry peers.
- In the last couple of years the Operating Margin of EXEL has declined.
- EXEL has a better Gross Margin (96.63%) than 96.56% of its industry peers.
- EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
- EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- EXEL has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
- EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- EXEL has an Altman-Z score of 12.49. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of EXEL (12.49) is better than 84.35% of its industry peers.
- EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.49 |
ROIC/WACC2.95
WACC8.93%
2.3 Liquidity
- EXEL has a Current Ratio of 3.75. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
- EXEL's Current ratio of 3.75 is in line compared to the rest of the industry. EXEL outperforms 45.42% of its industry peers.
- EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.68, EXEL perfoms like the industry average, outperforming 46.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
- EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
- Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
- Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 9.93% in the last year.
- The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
- Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.68% on average per year.
- EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y46.91%
EPS Next 2Y32.4%
EPS Next 3Y30.29%
EPS Next 5Y25.68%
Revenue Next Year7.7%
Revenue Next 2Y9.84%
Revenue Next 3Y11.53%
Revenue Next 5Y9.99%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 17.93 indicates a rather expensive valuation of EXEL.
- Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.23% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 28.18, EXEL is valued a bit cheaper.
- The Price/Forward Earnings ratio is 13.10, which indicates a correct valuation of EXEL.
- EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.95% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (25.51), we can say EXEL is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.93 | ||
| Fwd PE | 13.1 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 96.76% of the companies in the same industry.
- 96.95% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.61 | ||
| EV/EBITDA | 11.55 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as EXEL's earnings are expected to grow with 30.29% in the coming years.
PEG (NY)0.38
PEG (5Y)1.42
EPS Next 2Y32.4%
EPS Next 3Y30.29%
5. Dividend
5.1 Amount
- No dividends for EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:EXEL (2/4/2026, 12:39:52 PM)
42.495
-0.1 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-10 2026-02-10/amc
Inst Owners97.46%
Inst Owner Change-2.28%
Ins Owners2.18%
Ins Owner Change4.47%
Market Cap11.39B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target46.24 (8.81%)
Short Float %9.82%
Short Ratio10.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)0.12%
PT rev (3m)3.28%
EPS NQ rev (1m)8.63%
EPS NQ rev (3m)32.56%
EPS NY rev (1m)1.38%
EPS NY rev (3m)13.36%
Revenue NQ rev (1m)-0.69%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.93 | ||
| Fwd PE | 13.1 | ||
| P/S | 4.98 | ||
| P/FCF | 14.61 | ||
| P/OCF | 14.4 | ||
| P/B | 5.27 | ||
| P/tB | 5.43 | ||
| EV/EBITDA | 11.55 |
EPS(TTM)2.37
EY5.58%
EPS(NY)3.24
Fwd EY7.63%
FCF(TTM)2.91
FCFY6.84%
OCF(TTM)2.95
OCFY6.94%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.38
PEG (5Y)1.42
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.49 |
F-Score8
WACC8.93%
ROIC/WACC2.95
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y46.91%
EPS Next 2Y32.4%
EPS Next 3Y30.29%
EPS Next 5Y25.68%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.7%
Revenue Next 2Y9.84%
Revenue Next 3Y11.53%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.89%
EBIT Next 3Y25.82%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 46.91% in the next year.